APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Tumors Harboring Alterations In Ezh2 Or Members Of The Swi/snf Complex
  • Age: Between 12 years - 21 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patient must have enrolled onto APEC1621SC and must have been given a treatment assignment to MATCH to APEC1621C. 2. Patients must have radiographically measurable disease at the time of study enrollment. Patients with neuroblastoma who do not have measurable disease but have IBG+ evaluable disease are eligible. 3. Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy.

You may not be eligible for this study if the following are true:

  • 1. Patients who are currently receiving another investigational drug are not eligible. 2. Pregnant or Breast-Feeding 3. Patients who have an uncontrolled infection are not eligible. Disease


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.